New targets for drug development in asthma

Summary Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a total that is expected to rise to about 400 million over the next 15–20 years. Most asthmatic individuals respond well to the currently available treatments of inhaled corticosteroids and β-adrenergic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2008-09, Vol.372 (9643), p.1073-1087
Hauptverfasser:	Adcock, Ian M, Prof, Caramori, Gaetano, MD, Chung, K Fan, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones - therapeutic use Adrenergic beta-Agonists - therapeutic use Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Asthma Asthma - drug therapy Biological and medical sciences Cells Chemistry, Pharmaceutical - trends Chronic obstructive pulmonary disease, asthma Clinical medicine Corticoids Cytokines - drug effects Disease Drug therapy General aspects Humans Internal Medicine Medical sciences Monoclonal antibodies Oxidative Stress - drug effects Oxidizing agents Patients Pharmaceuticals Pneumology R&D Research & development Transcription Factors - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!